ClinicalTrials.gg
Not yet recruitingNCT07583589Updated May 13, 2026

Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of Nintedanib,Dextromethorphan and Nintedanib,Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by First Affiliated Hospital of Wenzhou Medical University. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by First Affiliated Hospital of Wenzhou Medical University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Planned enrollment
7th of 16
60 · median 49
Started
2026
the only one that year
Phase 2
3 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
First Affiliated Hospital of Wenzhou Medical University

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 2, and was the 16th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now.

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

Nintedanib combined with or without Dextromethorphan for the treatment of IPF, with FVC as the primary efficacy endpoint to evaluate its effectivenes.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥40 years old, regardless of gender;
  2. According to "2022 ATS/ERS/JRS/ALAT Guidelines", it was diagnosed as idiopathic pulmonary fibrosis (IPF);
  3. Lung function meets the following conditions during screening: forced vital capacity (FVC) ≥45% predicted value; The dispersion of carbon monoxide (DLco, corrected ) in a single breath is between 30% and 80% of the predicted value.
  4. HRCT images completed within 12 months before screening can be used to determine UIP mode;
  5. It is expected to complete the whole research plan, including 12 weeks of treatment and 1 week of follow-up;
  6. Willing to follow all the requirements of drug use, visit and data collection during the study period;
  7. Be able to understand the research content and sign the written ;
  8. Women of childbearing age provide negative pregnancy test results, and agree to take effective measures during the study period and within 3 months after the last administration; Male subjects with fertility also need to take effective contraception at the same time.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from other interstitial lung diseases caused by non-IPF reasons (such as connective tissue disease-related ILD, chronic allergic pneumonia, pneumoconiosis, drug-induced pneumonia, radiation lung disease, etc.);
  2. One or more Acute Exacerbation); of IPF occurred within 3 months before screening;
  3. Have received a lung transplant;
  4. Complicated with severe (GOLD III and above), severe asthma or other airway diseases that may interfere with FVC determination;
  5. The following systemic treatments were used within 4 weeks before screening: > 15 mg/d prednisone (or equivalent dose), cyclophosphamide, methotrexate, tuzumab, rituximab, mycophenolate mofetil, etc.
  6. Currently or in the past, allergic to Nidanib, dextromethorphan or any of its auxiliary ingredients;
  7. The following laboratory abnormalities exist: or AST >3×;; \<30 mL/min/1.73m²;
  8. Have a history of uncontrolled mental illness, epilepsy, central nervous system dysfunction, or may induce adverse reactions after using dextromethorphan;
  9. Being receiving drugs that may have serious drug interaction with dextromethorphan, such as monoamine oxidase inhibitor (MAOI) and selective serotonin reuptake inhibitor (SSRI), and unable to stop taking drugs;
  10. Pregnant or lactating women;
  11. At the time of screening, there are other major diseases or medical conditions that researchers think will significantly increase the risk and affect the treatment compliance or data interpretation;
  12. Interventional treatment of other clinical trials within 4 weeks before screening.
  13. Use Nidanib or pirfenidone for anti-fibrosis treatment within 8 weeks before screening;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Experimental: The dosage of Nintedanib is 150mg/100mg per dose, twice daily;The dosage of Dextromethorphan is 30mg per dose, twice daily.

    Drug: Nintedanib,Dextromethorphan

  • Placebo comparator
    Control group

    Control group:The dosage of Nintedanib is 150mg/100mg per dose, twice daily;Placebo take orally twice daily.

    Drug: Nintedanib,Placebo

Interventions

  • DrugNintedanib,Dextromethorphan

    Drug pages: NintedanibStudies of NintedanibNintedanib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DextromethorphanStudies of DextromethorphanDextromethorphan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dosage of Nitedanib is 150mg/100mg each time, twice a day, once in the morning and once in the evening, It is recommended to take it with meals. The dosage of Dextromethorphan sustained-release tablets is 30 mg, twice a day. It is recommended to take it orally 30 minutes after meals. For 12 weeks.

  • DrugNintedanib,Placebo

    Dosage of Nitedanib is 150mg/100mg each time, twice a day, once in the morning and once in the evening, with an interval of 12hours. It is recommended to take it with meals to reduce gastrointestinal adverse reactions. Placebo, twice a day, recommended to be taken in the morning and evening. For 12 weeks.

06

What researchers measure

Primary outcomes

  1. FVC

    Time frame: The change in FVC from baseline at week 12 after administration

Secondary outcomes

  1. Leicester Cough score (LCQ)

    Time frame: Change in score from baseline to week 12

  2. Symptoms and Effects Scale(L-PF)

    Time frame: Change in score from baseline to week 12

  3. Incidence Rate of Acute Aggravating Events(%predicted)

    Time frame: Incidence Rate of Acute Aggravating Events during the 12-week study period

  4. DLCO(%predictedl)

    Time frame: Change in score from baseline to week 12

  5. Incidence of Treatment-related adverse Events

    Time frame: The assessments need to be conducted four times at baseline and at weeks and 12 after medication

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2027, 9 months later.

Of 76 phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 50. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
May 13, 2026
StartEst.
May 12, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07583589
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
May 13, 2026
Start date
May 12, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
May 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Dextromethorphan

Start the discussion